COSCIENS Biopharma (CSCI) 6-K 15 May 24 Current report (foreign) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2024
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto ON
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 29,545	$ 34,016
Trade and other receivables	190	222
Inventory	64	66
Income taxes receivable	118	121
Prepaid expenses and other current assets	1,278	1,942
Total current assets	31,195	36,367
Non-current assets
Restricted cash equivalents	326	332
Property and equipment	271	317
Total non-current assets	597	649
Total assets	31,792	37,016
Current liabilities
Payables and accrued liabilities (note 4)	4,315	3,622
Provisions	422	429
Income taxes payable	109	111
Deferred revenues (note 3)	252	218
Lease liabilities	154	160
Total current liabilities	5,252	4,540
Non-current liabilities
Deferred revenues (note 3)	1,471	1,544
Lease liabilities	80	119
Employee future benefits (note 5)	12,019	12,617
Total non-current liabilities	13,570	14,280
Total liabilities	18,822	18,820
Shareholders’ equity
Share capital (note 6)	293,410	293,410
Warrants	5,085	5,085
Contributed surplus	90,718	90,710
Deficit	(375,264)	(369,831)
Accumulated other comprehensive loss	(979)	(1,178)
Total Shareholders’ equity	12,970	18,196
Total liabilities and shareholders’ equity	$ 31,792	$ 37,016

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Issued capital [member]	Warrants [member]	Contributed Surplus [member]	Retained earnings [member]	Accumulated other comprehensive income [member]	Total
Balance at Dec. 31, 2022	$ 293,410	$ 5,085	$ 90,332	$ (352,084)	$ (967)	$ 35,776
IfrsStatementLineItems [Line Items]
Net loss				(4,255)		(4,255)
Foreign currency translation adjustments					(168)	(168)
Actuarial loss on defined benefit plans				(162)		(162)
Comprehensive income				(4,417)	(168)	(4,585)
Share-based compensation costs			17			17
Balance at Mar. 31, 2023	293,410	5,085	90,349	(356,501)	(1,135)	31,208
Balance at Dec. 31, 2023	293,410	5,085	90,710	(369,831)	(1,178)	18,196
IfrsStatementLineItems [Line Items]
Net loss				(5,752)		(5,752)
Foreign currency translation adjustments					199	199
Actuarial loss on defined benefit plans				319		319
Comprehensive income				(5,433)	199	(5,234)
Share-based compensation costs			8			8
Balance at Mar. 31, 2024	$ 293,410	$ 5,085	$ 90,718	$ (375,264)	$ (979)	$ 12,970

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Profit or loss [abstract]
Revenues (note 3)		$ 4	$ 2,128
Expenses
Cost of sales		16	17
Research and development		2,584	4,012
Selling, general and administrative (note 10)		3,514	2,306
Total expenses		6,114	6,335
Loss from operations		(6,110)	(4,207)
Gain (loss) due to changes in foreign currency exchange rates		77	(59)
Interest income		285	13
Other finance costs		(4)	(2)
Net finance income (costs)		358	(48)
Loss before income taxes		(5,752)	(4,255)
Income tax recovery
Net loss		(5,752)	(4,255)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments		199	(168)
Items that will not be reclassified to profit or loss:
Actuarial gain (loss) on defined benefit plans (note 5)		319	(162)
Comprehensive loss		$ (5,234)	$ (4,585)
Basic loss per share		$ (4.74)	$ (3.51)
Diluted loss per share		$ (4.74)	$ (3.51)
Weighted average number of shares outstanding, basic	[1]	1,213,969	1,213,969
Weighted average number of shares outstanding, diluted	[1]	1,213,969	1,213,969
[1]On May [3], 2024, the Company’s shares were consolidated on a 1-for-4 reverse stock split, which has been reflected retrospectively in the financial statements and further discussed in note 6.

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss for the period	$ (5,752)	$ (4,255)
Items not affecting cash and cash equivalents:
Depreciation and amortization	44	40
Share-based compensation costs	8	17
Employee future benefits	130	135
Net foreign exchange differences	(6)	8
Amortization of deferred revenues		(760)
Provisions		(8)
Other non-cash items	5	1
Changes in operating assets and liabilities (note 7)	1,281	761
Net cash used in operating activities	(4,290)	(4,061)
Cash flows from financing activities
Payments on lease liabilities	(42)	(38)
Net cash used in financing activities	(42)	(38)
Cash flows from investing activities
Purchase of property and equipment	(5)	(2)
Net cash used in investing activities	(5)	(2)
Effect of exchange rate changes on cash and cash equivalents	(134)	50
Net change in cash and cash equivalents	(4,471)	(4,051)
Cash and cash equivalents – Beginning of period	34,016	50,611
Cash and cash equivalents – End of period	$ 29,545	$ 46,560

Business overview

Business overview	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Business overview	1. Business overview Summary of business Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen ® The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on May 14, 2024.

Basis of presentation

Basis of presentation	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Basis of presentation	2. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2023. The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements. New standards and amendments Several amendments apply for the first time in 2024, but do not have an impact on the interim condensed consolidated financial statements of the Company. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2023.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Revenue	3. Revenue The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2024 2023 Three months ended March 31, 2024 2023 $ $ Royalties 4 18 License fees - 760 Development services - 1,339 Supply chain - 11 Total 4 2,128 The Company recorded revenue for the transfer of services overtime for the three months ended March 31, 2024, $ nil 2,110 4 18 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Liabilities related to contracts with customers The following table provides a summary of deferred revenue balances: Summary of deferred revenue Current Non-current Total March 31, 2024 Current Non-current Total $ $ $ Pharmanovia 244 1,350 1,594 NK Meditech 8 121 129 Contract liabilities 252 1,471 1,723 Current Non-current Total December 31, 2023 Current Non-current Total $ $ $ Pharmanovia 209 1,420 1,629 NK Meditech 9 124 133 Contract liabilities 218 1,544 1,762

Payables and accrued liabilitie

Payables and accrued liabilities	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Payables and accrued liabilities	4. Payables and accrued liabilities Summary of detailed information about payables and accrued liabilities 2024 2023 Three months ended March 31, 2024 2023 $ $ Trade accounts payable 2,402 1,866 Accrued research and development costs 438 804 Accrued employee benefits 411 343 Payroll tax and other statutory liabilities 60 78 Other accrued liabilities 1,004 531 Payables and accrued liabilities 4,315 3,622 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Employee future benefits

Employee future benefits	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Employee future benefits	5. Employee future benefits The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset Three months ended March 31, 2024 Year ended December 31, 2023 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the year 23,622 98 23,720 21,750 Current service cost (residual value) 32 3 35 120 Interest cost 185 - 185 807 Actuarial loss (gain) arising from changes in financial assumptions (319 ) - (319 ) 1,213 Benefits paid (183 ) - (183 ) (815 ) Impact of foreign exchange rate changes (524 ) (3 ) (527 ) 645 Balances – End of the period 22,813 98 22,911 23,720 Change in plan assets Balances – Beginning of the year 11,103 - 11,103 10,591 Interest income from plan assets 88 - 88 396 Employer contributions 9 - 9 36 Employee contributions 3 - 3 13 Benefits paid (63 ) - (63 ) (266 ) Remeasurement of plan assets - - - 15 Impact of foreign exchange rate changes (248 ) - (248 ) 318 Balances – End of the year 10,892 - 10,892 11,103 Net liability of the unfunded plans 11,184 98 11,282 11,682 Net liability of the funded plans 737 - 737 935 Net amount recognized as Employee future benefits 11,921 98 12,019 12,617 Amounts recognized: In net loss 126 4 130 520 Actuarial gain (loss) on defined benefit plans in other comprehensive (gain) loss 319 - 319 (1,195 ) The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 3.40 3.30 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Shareholders_ equity

Shareholders’ equity	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Shareholders’ equity	6. Shareholders’ equity Share capital The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. 1-for-4 Summary of share capital Common shares Amount # $ Balance – December 31, 2023 1,213,969 293,410 - - Balance – March 31, 2024 1,213,969 293,410 Share-based compensation During the three months ended March 31, 2024, the Company granted nil 3,500 nil nil 8 17 Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – December 31, 2023 13,350 50.04 Forfeited (167 ) 42.04 Granted - - Balance – March 31, 2024 13,183 50.14 Stock options Weighted average exercise price # $ Balance – December 31, 2022 10,508 80.20 Granted 3,500 15.00 Balance – March 31, 2023 14,008 63.91 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Supplemental disclosure of cash flow information	7. Supplemental disclosure of cash flow information Summary of changes in operating assets and liabilities 2024 2023 Three months ended March 31, 2024 2023 $ $ Changes in operating assets and liabilities: Trade and other receivables 74 203 Inventory - 5 Prepaid expenses and other current assets 625 626 Payables and accrued liabilities 711 235 Deferred revenues - (154 ) Provision for restructuring and other costs - (9 ) Employee future benefits (129 ) (145 ) Increase (decrease) in operating assets and liabilities 1,281 761

Net loss per share

Net loss per share	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Net loss per share	8. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2024 2023 Three months ended March 31, 2024 2023 $ $ Net loss (5,752 ) (4,255 ) Basic and diluted weighted-average shares outstanding 1,213,969 1,213,969 Basic and diluted loss per share (4.74 ) (3.51 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 62,413 38,238 Warrants 114,405 114,405

Segment information

Segment information	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Segment information	9. Segment information The Company operates in a single

Related party transactions

Related party transactions	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Related party transactions	10. Related party transactions During the three months ended March 31, 2024, the Company recorded a termination benefit payment of $ 324 300 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Commitments

Commitments	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Commitments	11. Commitments Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 4,335 1 - 5 years 75 Total 4,410 In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $ 38,756

Subsequent event

Subsequent event	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Subsequent event	12. Subsequent event On December 14, 2023, the Company and Ceapro Inc. (“Ceapro”) jointly announced the signing of a definitive agreement to combine their operations in an all-stock merger of equals. Pursuant to the agreement, the transaction will be effected by way of a plan of arrangement under the Canada Business Corporations Act pursuant to which, following the 1-for-4 0.02360 0.47698 0.01 Following the closing of the Transaction, the former shareholders of Ceapro will own 50% of Aeterna and the pre-transaction securityholders of Aeterna will own the remaining 50%, assuming the exercise of all Transaction Warrants.

Basis of presentation (Policies

Basis of presentation (Policies)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
New standards and amendments	New standards and amendments Several amendments apply for the first time in 2024, but do not have an impact on the interim condensed consolidated financial statements of the Company. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)
Critical accounting estimates and judgements	Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2023.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of revenue from transfer of goods and services	The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2024 2023 Three months ended March 31, 2024 2023 $ $ Royalties 4 18 License fees - 760 Development services - 1,339 Supply chain - 11 Total 4 2,128
Summary of deferred revenue	The following table provides a summary of deferred revenue balances: Summary of deferred revenue Current Non-current Total March 31, 2024 Current Non-current Total $ $ $ Pharmanovia 244 1,350 1,594 NK Meditech 8 121 129 Contract liabilities 252 1,471 1,723 Current Non-current Total December 31, 2023 Current Non-current Total $ $ $ Pharmanovia 209 1,420 1,629 NK Meditech 9 124 133 Contract liabilities 218 1,544 1,762

Payables and accrued liabilit_2

Payables and accrued liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of detailed information about payables and accrued liabilities	Summary of detailed information about payables and accrued liabilities 2024 2023 Three months ended March 31, 2024 2023 $ $ Trade accounts payable 2,402 1,866 Accrued research and development costs 438 804 Accrued employee benefits 411 343 Payroll tax and other statutory liabilities 60 78 Other accrued liabilities 1,004 531 Payables and accrued liabilities 4,315 3,622

Employee future benefits (Table

Employee future benefits (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of net defined benefit liability asset	The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset Three months ended March 31, 2024 Year ended December 31, 2023 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the year 23,622 98 23,720 21,750 Current service cost (residual value) 32 3 35 120 Interest cost 185 - 185 807 Actuarial loss (gain) arising from changes in financial assumptions (319 ) - (319 ) 1,213 Benefits paid (183 ) - (183 ) (815 ) Impact of foreign exchange rate changes (524 ) (3 ) (527 ) 645 Balances – End of the period 22,813 98 22,911 23,720 Change in plan assets Balances – Beginning of the year 11,103 - 11,103 10,591 Interest income from plan assets 88 - 88 396 Employer contributions 9 - 9 36 Employee contributions 3 - 3 13 Benefits paid (63 ) - (63 ) (266 ) Remeasurement of plan assets - - - 15 Impact of foreign exchange rate changes (248 ) - (248 ) 318 Balances – End of the year 10,892 - 10,892 11,103 Net liability of the unfunded plans 11,184 98 11,282 11,682 Net liability of the funded plans 737 - 737 935 Net amount recognized as Employee future benefits 11,921 98 12,019 12,617 Amounts recognized: In net loss 126 4 130 520 Actuarial gain (loss) on defined benefit plans in other comprehensive (gain) loss 319 - 319 (1,195 )

Shareholders_ equity (Tables)

Shareholders’ equity (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of share capital	Summary of share capital Common shares Amount # $ Balance – December 31, 2023 1,213,969 293,410 - - Balance – March 31, 2024 1,213,969 293,410
Summary of number and weighted average exercise prices of share options	Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – December 31, 2023 13,350 50.04 Forfeited (167 ) 42.04 Granted - - Balance – March 31, 2024 13,183 50.14 Stock options Weighted average exercise price # $ Balance – December 31, 2022 10,508 80.20 Granted 3,500 15.00 Balance – March 31, 2023 14,008 63.91

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of changes in operating assets and liabilities	Summary of changes in operating assets and liabilities 2024 2023 Three months ended March 31, 2024 2023 $ $ Changes in operating assets and liabilities: Trade and other receivables 74 203 Inventory - 5 Prepaid expenses and other current assets 625 626 Payables and accrued liabilities 711 235 Deferred revenues - (154 ) Provision for restructuring and other costs - (9 ) Employee future benefits (129 ) (145 ) Increase (decrease) in operating assets and liabilities 1,281 761

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Summary of pertinent data relating to computation of basic and diluted net loss per share	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2024 2023 Three months ended March 31, 2024 2023 $ $ Net loss (5,752 ) (4,255 ) Basic and diluted weighted-average shares outstanding 1,213,969 1,213,969 Basic and diluted loss per share (4.74 ) (3.51 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 62,413 38,238 Warrants 114,405 114,405

Commitments (Tables)

Commitments (Tables)	3 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
Schedule of expected future minimum lease payments	Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 4,335 1 - 5 years 75 Total 4,410

Summary of revenue from transfe

Summary of revenue from transfer of goods and services (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Notes and other explanatory information [abstract]
Royalties	$ 4	$ 18
License fees		760
Development services		1,339
Supply chain		11
Total	$ 4	$ 2,128

Summary of deferred revenue (De

Summary of deferred revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
IfrsStatementLineItems [Line Items]
Current contract liabilities	$ 252	$ 218
Non-current contract liabilities	1,471	1,544
Contract liabilities	1,723	1,762
Pharmanovia [member]
IfrsStatementLineItems [Line Items]
Current contract liabilities	244	209
Non-current contract liabilities	1,350	1,420
Contract liabilities	1,594	1,629
NK meditech limited [member]
IfrsStatementLineItems [Line Items]
Current contract liabilities	8	9
Non-current contract liabilities	121	124
Contract liabilities	$ 129	$ 133

Summary of detailed information

Summary of detailed information about payables and accrued liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Notes and other explanatory information [abstract]
Trade accounts payable	$ 2,402		$ 1,866
Accrued research and development costs	438		804
Accrued employee benefits	411		343
Payroll tax and other statutory liabilities	60		78
Other accrued liabilities	1,004		531
Payables and accrued liabilities	$ 4,315	$ 3,622	$ 3,622

Summary of net defined benefit

Summary of net defined benefit liability asset (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Change in plan liabilities
Balances – Beginning of the year	$ 23,720	$ 21,750
Current service cost (residual value)	35	120
Interest cost	185	807
Actuarial loss (gain) arising from changes in financial assumptions	319	(1,213)
Benefits paid	(183)	(815)
Impact of foreign exchange rate changes	(527)	645
Balances – End of the period	22,911	23,720
Change in plan assets
Balances – Beginning of the year	11,103	10,591
Interest income from plan assets	88	396
Employer contributions	9	36
Employee contributions	3	13
Benefits paid	(63)	(266)
Remeasurement of plan assets		15
Impact of foreign exchange rate changes	(248)	318
Balances – End of the year	10,892	11,103
Net liability of the unfunded plans	11,282	11,682
Net liability of the funded plans	737	935
Net amount recognized as Employee future benefits	12,019	12,617
Amounts recognized:
In net loss	130	520
Actuarial gain (loss) on defined benefit plans in other comprehensive (gain) loss	319	(1,195)
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the year	23,622
Current service cost (residual value)	32
Interest cost	185
Actuarial loss (gain) arising from changes in financial assumptions	319
Benefits paid	(183)
Impact of foreign exchange rate changes	(524)
Balances – End of the period	22,813	23,622
Change in plan assets
Balances – Beginning of the year	11,103
Interest income from plan assets	88
Employer contributions	9
Employee contributions	3
Benefits paid	(63)
Remeasurement of plan assets
Impact of foreign exchange rate changes	(248)
Balances – End of the year	10,892	11,103
Net liability of the unfunded plans	11,184
Net liability of the funded plans	737
Net amount recognized as Employee future benefits	11,921
Amounts recognized:
In net loss	126
Actuarial gain (loss) on defined benefit plans in other comprehensive (gain) loss	319
Other benefit plans [member]
Change in plan liabilities
Balances – Beginning of the year	98
Current service cost (residual value)	3
Interest cost
Actuarial loss (gain) arising from changes in financial assumptions
Benefits paid
Impact of foreign exchange rate changes	(3)
Balances – End of the period	98	98
Change in plan assets
Balances – Beginning of the year
Interest income from plan assets
Employer contributions
Employee contributions
Benefits paid
Remeasurement of plan assets
Impact of foreign exchange rate changes
Balances – End of the year
Net liability of the unfunded plans	98
Net liability of the funded plans
Net amount recognized as Employee future benefits	98
Amounts recognized:
In net loss	4
Actuarial gain (loss) on defined benefit plans in other comprehensive (gain) loss

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
IfrsStatementLineItems [Line Items]
Revenues	$ 4	$ 2,128
Goods or services transferred over time [member]
IfrsStatementLineItems [Line Items]
Revenues		2,110
Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenues	$ 4	$ 18

Employee future benefits (Detai

Employee future benefits (Details Narrative)	Mar. 31, 2024	Dec. 31, 2023
Notes and other explanatory information [abstract]
Discount rate	3.40%	3.30%

Summary of share capital (Detai

Summary of share capital (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) shares
IfrsStatementLineItems [Line Items]
Balance	$ 18,196
Balance	$ 12,970
Issued capital [member]
IfrsStatementLineItems [Line Items]
Beginning balance, shares | shares	1,213,969
Balance	$ 293,410
Issuance of common shares, net of transaction costs, shares | shares
Issuance of common shares, net of transaction costs, amount
Ending balance, shares | shares	1,213,969
Balance	$ 293,410

Summary of number and weighted

Summary of number and weighted average exercise prices of share options (Details)	3 Months Ended
	Mar. 31, 2024 shares $ / shares	Mar. 31, 2023 shares $ / shares
Notes and other explanatory information [abstract]
Number of options, beginning | shares	13,350	10,508
Weighted average exercise price, beginning | $ / shares	$ 50.04	$ 80.20
Number of options, beginning | shares	(167)
Weighted average exercise price, beginning | $ / shares	$ 42.04
Number of options, beginning | shares		3,500
Weighted average exercise price, beginning | $ / shares		$ 15
Number of options, beginning | shares	13,183	14,008
Weighted average exercise price, beginning | $ / shares	$ 50.14	$ 63.91

Summary of changes in operating

Summary of changes in operating assets and liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Notes and other explanatory information [abstract]
Trade and other receivables	$ 74	$ 203
Inventory		5
Prepaid expenses and other current assets	625	626
Payables and accrued liabilities	711	235
Deferred revenues		(154)
Provision for restructuring and other costs		(9)
Employee future benefits	(129)	(145)
Increase (decrease) in operating assets and liabilities	$ 1,281	$ 761

Summary of pertinent data relat

Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
IfrsStatementLineItems [Line Items]
Net loss		$ (5,752)	$ (4,255)
Basic weighted-average number of shares outstanding	[1]	1,213,969	1,213,969
Diluted weighted-average number of shares outstanding	[1]	1,213,969	1,213,969
Basic loss per share		$ (4.74)	$ (3.51)
Diluted loss per share		$ (4.74)	$ (3.51)
Employee stock option and deferred stock units [member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Warrants		62,413	38,238
Warrants [member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Warrants		114,405	114,405
[1]On May [3], 2024, the Company’s shares were consolidated on a 1-for-4 reverse stock split, which has been reflected retrospectively in the financial statements and further discussed in note 6.

Shareholders_ equity (Details N

Shareholders’ equity (Details Narrative) $ in Thousands			3 Months Ended
	May 03, 2024	May 01, 2024	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 USD ($) shares
IfrsStatementLineItems [Line Items]
Number of options, granted				3,500
Compensation expenses | $			$ 8	$ 17
Long term incentive plan [member]
IfrsStatementLineItems [Line Items]
Number of options, granted
Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Reverse stock split	1-for-4
Nonadjusting event [member] | Board of directors [member]
IfrsStatementLineItems [Line Items]
Reverse stock split		1-for-4

Segment information (Details Na

Segment information (Details Narrative)	3 Months Ended
	Mar. 31, 2024 Integer
Notes and other explanatory information [abstract]
Number of operating segments	1

Schedule of expected future min

Schedule of expected future minimum lease payments (Details) $ in Thousands	Mar. 31, 2024 USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 4,410
Not later than one year [member]
IfrsStatementLineItems [Line Items]
Total	4,335
Later than one year and not later than five years [member]
IfrsStatementLineItems [Line Items]
Total	$ 75

Related party transactions (Det

Related party transactions (Details Narrative) - 3 months ended Mar. 31, 2024	USD ($)	EUR (€)
Notes and other explanatory information [abstract]
Termination benefits expense	$ 324	€ 300

Commitments (Details Narrative)

Commitments (Details Narrative) $ in Thousands	Mar. 31, 2024 USD ($)
IfrsStatementLineItems [Line Items]
Minimum lease payments net	$ 4,410
Top of range [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments net	$ 38,756

Subsequent event (Details Narra

Subsequent event (Details Narrative) - $ / shares	May 03, 2024	Dec. 14, 2023
Definitive agreement [member] | Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Share purchase warrants price per share		$ 0.47698
Nominal exercise price		$ 0.01
Description of transaction warrants		Following the closing of the Transaction, the former shareholders of Ceapro will own 50% of Aeterna and the pre-transaction securityholders of Aeterna will own the remaining 50%, assuming the exercise of all Transaction Warrants.
Definitive agreement [member] | Ceapro Inc. [member]
IfrsStatementLineItems [Line Items]
Common share exchanged price per share		$ 0.02360
Nonadjusting event [member]
IfrsStatementLineItems [Line Items]
Reverse stock split	1-for-4